The multi-center, double-masked, randomized sham-controlled LEAD trial1 has shown that 2RT™ Retinal Rejuvenation from Ellex® achieves a 77% reduction in the rate of progression to late-stage AMD in selected patients, compared to sham non-treated group.*
1. Guymer RH, Wu Z, Hodgson LAB, et al. Sub-Threshold Nanosecond Laser Intervention in Age-Related Macular Degeneration: The LEAD Randomized Controlled Clinical Trial. Ophthalmology. 2018. *Post hoc analysis in patients without coexistent reticular pseudodrusen (RPD). 2RT has a CE Mark (Conformité Européene) for treatment in patients with early AMD where it can produce bilateral improvements in macular appearance and function. 2RT has a CE Mark (Conformité Européene) and US Food and Drug Administration (FDA) (510k) Market release for the treatment of Clinically Significant Macula Edema (CSME). 2RT is not approved for sale in the USA for the indication of early AMD.
Groundbreaking LiGHT Trial1
“Selective laser trabeculoplasty should be offered as first-line treatment for open angle glaucoma and ocular hypertension, supporting a change in clinical practice.”
Break free from non-compliance and see the light with superior efficacy and safety with SLT from Ellex®, the global market leader.
1LiGHT study, The Lancet. 393.10175
Every day, Ellex collaborates with leading physicians, teaching institutions and universities to discover, develop and deliver new technologies for the safe and effective treatment of a broad range of eye conditions.
Since 1985, we've made it our mission to invest in the healing power of ophthalmic laser technology and help to transform the sight and the lives of people across the globe.
Today, more than 35,000 Ellex ophthalmic laser and ultrasound systems, along with iTrack™ — our solution for minimally invasive glaucoma surgery — are in use in over 100 countries around the world, achieving ophthalmic outcomes once never thought possible — safely, effectively, accurately and consistently.